IPSEY Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 21:11):

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...

Stats
Šios dienos apimtis	479.00
Vidutinė apimtis	1 524.00
Rinkos kapitalizacija	9.94B
Last Dividend	$0.324 ( 2023-06-02 )
Next Dividend	$0 ( N/A )
P/E	14.96
ATR14	$0 (0.00%)

Ipsen S.A. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ipsen S.A. Finansinės ataskaitos

Annual	2023
Pajamos:	$3.13B
Bruto pelnas:	$2.35B (75.10 %)
EPS:	$7.79

FY	2023
Pajamos:	$3.13B
Bruto pelnas:	$2.35B (75.10 %)
EPS:	$7.79

FY	2022
Pajamos:	$3.16B
Bruto pelnas:	$2.63B (83.28 %)
EPS:	$1.970

FY	2021
Pajamos:	$3.00B
Bruto pelnas:	$2.46B (82.06 %)
EPS:	$1.948

Financial Reports:

No articles found.

Ipsen S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.324 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ipsen S.A. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.15 - Stable (22.93%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.262	2013-06-11
Last Dividend	$0.324	2023-06-02
Next Dividend	$0	N/A
Payout Date	2023-06-27
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$3.05	--
Avg. Dividend % Per Year	0.00%	--
Score	3.56	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.15
Div. Directional Score	9.82	--

Next Divdend (Est)
(2025-03-31)

$0.339 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.56

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
VTKLY	Ex Dividend Knight	2023-07-20	Semi-Annually	0.00%
LNVGY	Ex Dividend Knight	2023-07-26	Annually	0.00%
CKHGY	Ex Dividend Knight	2023-05-11	Annually	0.00%
SGPYY	Ex Dividend Knight	2023-06-01	Semi-Annually	0.00%
GMVHY	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
AILLO	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
NACB	Ex Dividend Junior	2023-08-15	Quarterly	0.00%
CPKF	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
SZLMY	Ex Dividend Junior	2023-05-03	Annually	0.00%
HONT	Ex Dividend Junior	2023-08-14	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.82	[0 - 0.5]
returnOnAssetsTTM	0.102	1.200	6.60	7.92	[0 - 0.3]
returnOnEquityTTM	0.178	1.500	9.13	10.00	[0.1 - 1]
payoutRatioTTM	0.155	-1.000	8.45	-8.45	[0 - 1]
currentRatioTTM	1.167	0.800	9.17	7.33	[1 - 3]
quickRatioTTM	0.864	0.800	9.63	7.70	[0.8 - 2.5]
cashRatioTTM	0.325	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.0626	-1.500	8.96	-10.00	[0 - 0.6]
interestCoverageTTM	37.44	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
freeCashFlowPerShareTTM	7.99	2.00	6.00	10.00	[0 - 20]
debtEquityRatioTTM	0.103	-1.500	9.59	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.817	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.314	1.000	5.73	5.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.13	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.495	0.800	-0.0358	-0.0286	[0.5 - 2]
Total Score				13.49

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.63	1.000	9.73	0	[1 - 100]
returnOnEquityTTM	0.178	2.50	9.44	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	7.99	2.00	7.34	10.00	[0 - 30]
dividendYielPercentageTTM	1.145	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
payoutRatioTTM	0.155	1.500	8.45	-8.45	[0 - 1]
pegRatioTTM	0.0973	1.500	-2.68	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.270	1.000	5.76	0	[0.1 - 0.5]
Total Score				6.15

Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.